医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NCKU Research Team Reveals Key Mechanism in Lung Cancer

2014年09月25日 PM06:29
このエントリーをはてなブックマークに追加


 

TAINAN, Taiwan

Lung cancer remains one of the most common and malignant cancers worldwide. A Tainan-based research team from National Cheng Kung University (NCKU) has discovered Rab37, a protein in humans which is a critical regulator of vesicle trafficking, has played a vital role in inhibition of cancer metastasis.

The team led by NCKU Distinguished Professor Dr. Yi-Ching Wang from the Department of Pharmacology and Institute of Basic Medical Science, College of Medicine, made major medical breakthrough in tumour treatment, the university revealed at a press conference in Taipei on September 25.

Their research titled “Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis” has been published in the September issue of Nature Communications.

“What we’ve discovered will help clinicians to better treat patients with lung cancer,” said Dr. Wang.

She noted that Rab-controlled trafficking pathways have been involved in tumorigenesis.

She also explained, Rab37 suppresses metastasis by regulating the exocytosis of tissue inhibitor of metalloproteinase 1 (TIMP1) to repress matrix metalloproteinase 9 (MMP9) and represents a novel prognostic marker for lung cancer.

“We address the metastasis suppressive function of Rab37 using secretomics, cell, animal and clinical analyses,” Dr. Wang added.

The study shows that TIMP1is a novel cargo of Rab37, according to Dr. Wang, and lung cancer patients with metastasis show low Rab37 protein expression coinciding with low TIMP1 in tumours.

Dr. Wang’s team has identified Rab37 as a novel metastasis suppressor Rab that functions through the TIMP1-MMP9 pathway and has significant prognostic power.

CONTACT

National Cheng Kung University
Sonia Chuang, +886-6-275-7575 Ext.
50042
News Center
sonia20@mail.ncku.edu.tw
Fax:
+886-6-238-9919
NCKU news: http://news-en.secr.ncku.edu.tw/bin/home.php

同じカテゴリーの記事 

  • AtriCure已就在中国销售AtriClip®器械获得监管批准
  • ベイジーン、米国に生物製剤製造および臨床研究開発の旗艦施設を開設し、世界のより多くの患者に医薬品を届けるためのグローバルな拡大を継続
  • KBIバイオファーマがFDA検閲を通過、世界的な大手製薬会社との商業契約を延長・拡大
  • 继成功通过FDA检查后,KBI Biopharma续签并扩大了与全球领先制药公司的商业合同
  • BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers